293 related articles for article (PubMed ID: 24867051)
1. Breast cancer immunotherapy: monoclonal antibodies and peptide-based vaccines.
Mohit E; Hashemi A; Allahyari M
Expert Rev Clin Immunol; 2014 Jul; 10(7):927-61. PubMed ID: 24867051
[TBL] [Abstract][Full Text] [Related]
2. Vaccination for the prevention and treatment of breast cancer with special focus on Her-2/neu peptide vaccines.
Wiedermann U; Davis AB; Zielinski CC
Breast Cancer Res Treat; 2013 Feb; 138(1):1-12. PubMed ID: 23340862
[TBL] [Abstract][Full Text] [Related]
3. Immunologic approaches to breast cancer treatment.
Sabel MS; Nehs MA
Surg Oncol Clin N Am; 2005 Jan; 14(1):1-31, v. PubMed ID: 15541997
[TBL] [Abstract][Full Text] [Related]
4. Exosomal pMHC-I complex targets T cell-based vaccine to directly stimulate CTL responses leading to antitumor immunity in transgenic FVBneuN and HLA-A2/HER2 mice and eradicating trastuzumab-resistant tumor in athymic nude mice.
Wang L; Xie Y; Ahmed KA; Ahmed S; Sami A; Chibbar R; Xu Q; Kane SE; Hao S; Mulligan SJ; Xiang J
Breast Cancer Res Treat; 2013 Jul; 140(2):273-84. PubMed ID: 23881522
[TBL] [Abstract][Full Text] [Related]
5. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine.
Disis ML; Grabstein KH; Sleath PR; Cheever MA
Clin Cancer Res; 1999 Jun; 5(6):1289-97. PubMed ID: 10389911
[TBL] [Abstract][Full Text] [Related]
6. Investigating the combination of trastuzumab and HER2/neu peptide vaccines for the treatment of breast cancer.
Mittendorf EA; Storrer CE; Shriver CD; Ponniah S; Peoples GE
Ann Surg Oncol; 2006 Aug; 13(8):1085-98. PubMed ID: 16865596
[TBL] [Abstract][Full Text] [Related]
7. [Anti-HER2 vaccines: The HER2 immunotargeting future?].
Ladjemi MZ; Jacot W; Pèlegrin A; Navarro-Teulon I
Pathol Biol (Paris); 2011 Jun; 59(3):173-82. PubMed ID: 19481373
[TBL] [Abstract][Full Text] [Related]
8. 13. New biological therapies for breast cancer.
Plunkett TA; Miles DW
Int J Clin Pract; 2002 May; 56(4):261-6. PubMed ID: 12074208
[TBL] [Abstract][Full Text] [Related]
9. Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer.
Emens LA
Am J Ther; 2005; 12(3):243-53. PubMed ID: 15891269
[TBL] [Abstract][Full Text] [Related]
10. Breast cancer vaccines: maximizing cancer treatment by tapping into host immunity.
Emens LA; Reilly RT; Jaffee EM
Endocr Relat Cancer; 2005 Mar; 12(1):1-17. PubMed ID: 15788636
[TBL] [Abstract][Full Text] [Related]
11. Targeting fatty acid synthase-driven lipid rafts: a novel strategy to overcome trastuzumab resistance in breast cancer cells.
Menendez JA; Vellon L; Lupu R
Med Hypotheses; 2005; 64(5):997-1001. PubMed ID: 15780499
[TBL] [Abstract][Full Text] [Related]
12. Anti-ErbB-2 monoclonal antibodies and ErbB-2-directed vaccines.
Yip YL; Ward RL
Cancer Immunol Immunother; 2002 Jan; 50(11):569-87. PubMed ID: 11807621
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant therapy with trastuzumab for HER-2/neu-positive breast cancer.
Gonzalez-Angulo AM; Hortobágyi GN; Esteva FJ
Oncologist; 2006 Sep; 11(8):857-67. PubMed ID: 16951389
[TBL] [Abstract][Full Text] [Related]
14. Toward a breast cancer vaccine: work in progress.
Emens LA; Jaffee EM
Oncology (Williston Park); 2003 Sep; 17(9):1200-11; discussion 1214, 1217-8. PubMed ID: 14569849
[TBL] [Abstract][Full Text] [Related]
15. HER2-Positive Breast Cancer Immunotherapy: A Focus on Vaccine Development.
Arab A; Yazdian-Robati R; Behravan J
Arch Immunol Ther Exp (Warsz); 2020 Jan; 68(1):2. PubMed ID: 31915932
[TBL] [Abstract][Full Text] [Related]
16. MUC1-based recombinant Bacillus Calmette-Guerin vaccines as candidates for breast cancer immunotherapy.
Yuan S; Shi C; Liu L; Han W
Expert Opin Biol Ther; 2010 Jul; 10(7):1037-48. PubMed ID: 20420512
[TBL] [Abstract][Full Text] [Related]
17. Antibodies and vaccines--hope or illusion?
Jäger D; Knuth A
Breast; 2005 Dec; 14(6):631-5. PubMed ID: 16242931
[TBL] [Abstract][Full Text] [Related]
18. The impact of HER2/neu expression level on response to the E75 vaccine: from U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02.
Benavides LC; Gates JD; Carmichael MG; Patil R; Holmes JP; Hueman MT; Mittendorf EA; Craig D; Stojadinovic A; Ponniah S; Peoples GE
Clin Cancer Res; 2009 Apr; 15(8):2895-904. PubMed ID: 19351776
[TBL] [Abstract][Full Text] [Related]
19. Perspectives of immunotherapy in metastatic breast cancer.
Lüftner D; Pollmann D; Schildhauer S; Sehouli J; Possinger K
Anticancer Res; 2005; 25(6C):4599-604. PubMed ID: 16334149
[TBL] [Abstract][Full Text] [Related]
20. Current immunotherapeutic strategies in breast cancer.
Carson WE; Liang MI
Surg Oncol Clin N Am; 2007 Oct; 16(4):841-60, ix. PubMed ID: 18022548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]